<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141370">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02081183</url>
  </required_header>
  <id_info>
    <org_study_id>ML18989</org_study_id>
    <nct_id>NCT02081183</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis</brief_title>
  <official_title>A Study to Evaluate the Efficacy of CellCept, Administered in a Sequential Treatment Scheme, in Delaying Progressive Renal Damage in Patients With Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>Venezuela: Instituto Nacional de Higiene &quot;Rafael Rangel&quot;</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the efficacy of CellCept (0.5-2g/day po) and cyclophosphamide
      (0.5-1g/m2 quarterly) as maintenance treatment for patients with lupus nephritis. All
      patients will receive induction treatment with cyclophosphamide (0.5-1g/m2 monthly) for 6
      months, and will then be randomized to the maintenance phase of the study for a further 6
      months, followed by 6 months of treatment-free follow-up. The anticipated time on study
      treatment is 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Creatinine clearance</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary protein</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum albumin</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>MMF, Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction Phase (Months 1 through 6): Cyclophosphamide, 0.5 - 1 grams per square meter (g/m2) intravenous (i.v.) pulse once per month. Concurrent prednisone, 1 milligram per kilogram per day (mg/kg/day) gradually reduced to 10 mg/day orally (p.o.).
Maintenance Phase (Months 7 through 12): mycophenolate mofetil (MMF), 1 g/day, p.o. twice daily (b.i.d.) for 2 weeks; 1.5 g/day p.o. three times daily (t.i.d.) for the next 2 weeks; 2 g/day p.o. b.i.d. for the remainder of the Maintenance Phase. Concurrent prednisone, as in the Induction Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Cyclophosphamide, Prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction Phase (Months 1 through 6): Cyclophosphamide, 0.5 - 1 g/m2 i.v. pulse once per month. Concurrent prednisone, 1 mg/kg/day p.o. gradually reduced to 10 mg/day p.o.
Maintenance Phase (Months 7 through 12): Cyclophosphamide, 0.5-1 g/m2 i.v. pulse every 3 months. Concurrent prednisone, as in the Induction Phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil (MMF)</intervention_name>
    <description>1 g/day, p.o. b.i.d. for 2 weeks; 1.5 g/day p.o. t.i.d. for the next 2 weeks; and 2 g/day p.o. b.i.d. for the remainder of the Maintenance Phase.</description>
    <arm_group_label>MMF, Prednisone</arm_group_label>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide, Maintenance Phase</intervention_name>
    <description>0.5-1 g/m2 i.v. pulse every 3 months</description>
    <arm_group_label>Maintenance Cyclophosphamide, Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide, Induction Phase</intervention_name>
    <description>0.5 - 1 g/m2 i.v. pulse once per month</description>
    <arm_group_label>MMF, Prednisone</arm_group_label>
    <arm_group_label>Maintenance Cyclophosphamide, Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>1 mg/kg p.o. once per day; reduced by 5 mg every 2 weeks up to 20 mg/day; followed by a reduction of 2.5 mg every 2 weeks until reaching the maintenance phase of 10 mg/day.</description>
    <arm_group_label>MMF, Prednisone</arm_group_label>
    <arm_group_label>Maintenance Cyclophosphamide, Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients &gt;=18 years of age;

          -  diagnosis of systemic lupus erythematosus and lupus nephritis (class III, IV or V).

        Exclusion Criteria:

          -  patients who have received cytotoxic drugs in previous 8 weeks;

          -  systemic infections;

          -  hepatitis B or C, or HIV.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Chair</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Barquisimeto</city>
        <zip>3005</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caracas</city>
        <zip>1040</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Venezuela</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lupus Nephritis</mesh_term>
    <mesh_term>Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
